A multicenter, randomized, placebo-controlled trial for cilostazol in patients with mild cognitive impairment: The COMCID study protocol

INTRODUCTION: There are currently no effective treatments preventing conversion from mild cognitive impairment (MCI) to Alzheimer's disease. Cilostazol is a selective type-3 phosphodiesterase inhibitor that ameliorates accumulation of amyloid-β and has prevented cognitive decline in rodent mode...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Alzheimers Dement (N Y)
मुख्य लेखकों: Saito, Satoshi, Kojima, Shinsuke, Oishi, Naoya, Kakuta, Ryosuke, Maki, Takakuni, Yasuno, Fumihiko, Nagatsuka, Kazuyuki, Yamamoto, Haruko, Fukuyama, Hidenao, Fukushima, Masanori, Ihara, Masafumi
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Elsevier 2016
विषय:
Featured Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5651350/
https://ncbi.nlm.nih.gov/pubmed/29067312
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2016.10.001
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन